



71 11-12-03.

1617

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Batra et al.)
Serial No.: 09/894,921)
Docket No.: 20243CA)
Filed: June 28, 2001)
For: "COMPRESSED TABLET FORMULATION")

Examiner:
Sharareh, Shahnam J.
Art Unit:
1617

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RECEIVED
NOV 17 2003
TECH CENTER 1600/2900

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT 11-10-03
EXPRESS MAIL NO. 2V32315234245
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313-1450.
MAILED BY [signature]
DATE Nov 10 2003

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with 37 C.F.R. 1.97, submitted herewith on the attached form is a list of patents, publications, or other information. Copies of the cited references are enclosed. The submission and listing of these references is not to be construed as an admission that any of the submitted references is "prior art" with respect to the claimed invention. In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

Each item of information contained herein was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months before the filing of this information disclosure statement. The following are comments on three of documents in the attached list:

1. Document D3 is in Spanish, but translations of selected parts of the text are in parentheses. The document discloses certain HIV-1 protease inhibitors (especially saquinavir, ritonavir, indinavir and nelfinavir), and provides a brief discussion of clinical studies, resistance, adverse effects and metabolism. There is no mention of efavirenz. This document has essentially no relevance to the claimed subject matter.

2. Document D4 is also in Spanish, but translations of selected parts of the text are in parentheses. The document lists the principal groups of HIV antivirals

including efavirenz. This document has essentially no relevance to the claimed subject matter.

3. Document D5 is a portion of a 1995 edition of Remington's Pharmaceutical Sciences. Pages 859-863 closely correspond to Remington's Pharmaceutical Sciences, 19th edition, 1995, pp. 1616-1620, which is already of record. Pages 865-869 of Document C provide a general description of granulation methods. This document provides general technical information of interest as background with respect to the claimed invention, but is not otherwise relevant.

It is requested that the Examiner consider the cited references as part of the examination of the subject application, make the references of record, and return an initialed copy of the attached form with the next communication to Applicants.

Since this statement is being filed before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 C.F.R. 1.114, no fee is believed to be due.

Respectfully submitted,

By: Kenneth R. Walton
Kenneth R. Walton, Reg. No. 32,951
Attorney for Applicants
MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
Tel.: (732) 594-3462

Date: November 10, 2003

STATEMENT BY APPLICANT

COMPLETE IF KNOWN

Attorney Docket Number 20243CA

TECH CENTER 1600/2900

Sheet

1

of

2

[illegible][illegible]Date
Considered

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

NOV 10 2003

(use as ~~many~~ many sheets as necessary)

Sheet

2

of

2

Attorney Docket Number

20243CA

COMPLETE IF KNOWN**Application Number**

09/894,921

Filing Date

June 28, 2003

First Named Inventor

Batra et al.

Group Art Unit

1617

Examiner Name

Sharareh, Shahn timer J.

NON PATENT LITERATURE DOCUMENTS

Examiner
Initials*Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

D3.

"Los Inhibidores de La Proteasa Del VIH-1", 1997,
<http://www.prevenir.com/salud/sida/inhibid-proteasa.html>.

D4.

"Tratamiento con Antirretrovirales", 1997, <http://www.prevenir.com/salud/sida/tratamiento.html>.

D5.

Remington's Pharmaceutical Sciences, 1995, pp. 859-869.

D6.

L.M. Prescott, "Antimicrobial Agents and Chemotherapy" , 1997, Vol. X, No. 12 , <http://thebody.com/bp/dec97/anti.html>.

Examiner
Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003